



About us,

Encefa is a biopharmaceutical company stemming from the Pitié Salpêtrière Hospital and was founded in 2016.

NC-drugs act very specifically on CD38, an age-related target highly expressed by suffering cells and pro-inflammatory cells, to directly regulate their autophagy and energy metabolism.

An unprecedented mechanism that reinstates health in degenerative cells and represses inflammation.

So far, many advantages discovered :

- Combined actions on different pathological component
- Strong efficacy POC in vitro, ex vivo and in vivo
- Preliminary safe results in vivo at high doses (few off-target effects).

Therefore, by its pleiotropic action, ENCEFA’s compound has the potential to become game-changing players in the area of neurodegenerative, Auto-Immune and Inflammatory diseases : ALS, Multiple Sclerosis, Parkinson, Alzheimer, Rheumatoid Arthritis, NASH, T2DM...



LAURENCE BRESSAC
(CO-FOUNDER & CEO)




DAMIEN TOULORGE
(CO-FOUNDER & CSO)



SERGE GUERREIRO
(CO-FOUNDER & CSO)

Our Pipeline



Contact Us,

Adress : ENVA

7 avenue du Général de Gaulle - Bâtiment August Chauveau
94700 Maison Alfort – France EU

Email : contact@encefa.com